Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDGN-002 in Moderate to Severe Crohn's Disease or Ulcerative Colitis
NCT03169894Phase 1Terminated
- Sponsor
- Avalo Therapeutics
- Start
- Jul 2017
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quisovalimab in Crohn's disease and ulcerative colitis (UC), sponsored by Avalo Therapeutics. Primary endpoint: Simple Endoscopic Score for Crohn's Disease at Day 56. Started Jul 2017; status: terminated.
02
Drugs
quisovalimab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03169894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169894.